ESMO 2023 | Predictive biomarkers for adjuvant/neoadjuvant therapies in patients receiving IO for NSCLC

Nicholas Girard, MD, PhD, Institut Curie, Paris, France, discusses biomarkers that can predict if a patient will require neoadjuvant chemotherapy pre-surgery and adjuvant chemotherapy post-surgery to avoid disease recurrence in non-small cell lung cancer. Dr Girard mentions key prognostic components such PD-L1, EGFR, ALK and minimal residual disease (MRD). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.